Asthma patients on dupixent: a closer look at Real-Life results

NCT ID NCT04550962

Ongoing Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Feb 16, 2026 · Last updated May 21, 2026 · Updated 13 times

Summary

This study follows 376 asthma patients aged 12 and older who are starting Dupixent in everyday medical practice. Researchers will collect information on patients' medical history, how they use the drug, and how well it controls their asthma. The goal is to understand real-world effectiveness and safety, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigational Site Number : 0320001

Ciudad Autonoma Bs As, C1121ABE, Argentina
Investigational Site Number : 0320004

Santa Fe, 3000, Argentina
Investigational Site Number : 0320005

La Plata, Buenos Aires, B1900BNN, Argentina
Investigational Site Number : 0320006

Villa Rosa, Buenos Aires, 1631, Argentina
Investigational Site Number : 0320008

Ciudad Autonoma Buenos Aires, C1425BEN, Argentina
Investigational Site Number : 0320009

San Miguel de Tucumán, T4000IAI, Argentina
Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, 7500692, Chile
Investigational Site Number : 1520002

Quillota, Valparaiso, 2260877, Chile
Investigational Site Number : 1700003

Bucaramanga, Colombia
Investigational Site Number : 1700004

Bogotá, Colombia
Investigational Site Number : 1700009

Barranquilla, 080001, Colombia
Investigational Site Number : 3760001

Kfar Saba, 4428164, Israel
Investigational Site Number : 3760003

Jerusalem, 91120, Israel
Investigational Site Number : 3760004

Ashkelon, 78278, Israel
Investigational Site Number : 3760005

Jerusalem, 91031, Israel
Investigational Site Number : 3760006

Rehovot, 7642001, Israel
Investigational Site Number : 3760007

Tel Aviv, 64239, Israel
Investigational Site Number : 3760008

Ashdod, 7747629, Israel
Investigational Site Number : 4140001

Kuwait City, 00000, Kuwait
Investigational Site Number : 4220001

Beirut, Lebanon
Investigational Site Number : 4220002

Beirut, 11 0236, Lebanon
Investigational Site Number : 4220003

El Achrafiyé, Lebanon
Investigational Site Number : 4840003

Durango, 34000, Mexico
Investigational Site Number : 6340001

Doha, Qatar
Investigational Site Number : 6430002

Stavropol, 355020, Russia
Investigational Site Number : 6430004

Moscow, 115522, Russia
Investigational Site Number : 6430005

Chelyabinsk, 454091, Russia
Investigational Site Number : 6430006

Rostov-on-Don, 344012, Russia
Investigational Site Number : 6430007

Moscow, 105077, Russia
Investigational Site Number : 6430008

Saratov, 410012, Russia
Investigational Site Number : 6820001

Riyadh, 12713, Saudi Arabia
Investigational Site Number : 6820002

Riyadh, 11525, Saudi Arabia
Investigational Site Number : 6820004

Mecca, 24246, Saudi Arabia
Investigational Site Number : 6820005

Jeddah, 23433, Saudi Arabia
Investigational Site Number : 7020001

Singapore, 169308, Singapore
Investigational Site Number : 7020002

Singapore, 119074, Singapore
Investigational Site Number : 7840001

Dubai, 4545, United Arab Emirates
Investigational Site Number : 7840002

Sharjah city, 3499, United Arab Emirates
Investigational Site Number : 7840004

Sharjah city, 00000, United Arab Emirates
Investigational Site Number : 7840006

Abu Dhabi, 0000, United Arab Emirates
Investigational Site Number : 7840007

Dubai, 2, United Arab Emirates

Conditions

Explore the condition pages connected to this study.

ASTHMA